Abstract Breast cancer patients often develop bone metastasis evidenced by osteolytic lesions, leading to severe pain and bone fracture. Attenuation of breast cancer metastasis to bone and associated osteolysis by fish oil, rich in EPA and DHA, has been demonstrated previously. However, it was not known whether EPA and DHA differentially or similarly affect breast cancer bone metastasis and associated osteolysis. In vitro culture of parental and luciferase gene encoded MDA-MB-231 human breast cancer cell lines treated with EPA and DHA revealed that DHA inhibits proliferation and invasion of breast cancer cells more potently than EPA. Intra-cardiac injection of parental and luciferase gene encoded MDA-MB-231 cells to athymic NCr nu/nu mice demonstrated that DHA-treated mice had significantly less breast cancer cell burden in bone, and also significantly less osteolytic lesions than EPA-treated mice. In vivo cell migration assay as measured by luciferase intensity revealed that DHA attenuated cell migration specifically to the bone. Moreover, the DHAtreated group showed reduced levels of CD44 and TRAP positive area in bone compared to EPA-treated group. Breast cancer cell burden and osteolytic lesions were also examined in intra-tibially breast cancer cell injected mice and found less breast cancer cell growth and associated osteolysis in DHA-treated mice as compared to EPAtreated mice. Finally, doxorubicin-resistant MCF-7 (MCF7dox) human breast cancer cell line was used to examine if DHA can improve sensitization of MCF-7dox cells to doxorubicin. DHA improved the inhibitory effect of doxorubicin on proliferation and invasion of MCF-7dox cells. Interestingly, drug resistance gene P-gp was also down-regulated in DHA plus doxorubicin-treated cells. In conclusion, DHA attenuates breast cancer bone metastasis and associated osteolysis more potently than EPA, possibly by inhibiting migration of breast cancer cell to the bone as well as by inhibiting osteoclastic bone resorption.
Introduction
Metastatic bone disease is a major cause of morbidity in breast cancer patients. An estimated 192,370 women in USA were diagnosed with, and 40,170 women died of breast cancer in 2009. Among these, many are likely to develop bone metastasis and pain leading to poor quality of life. The Western diet is rich in x-6 fatty acids (FA), and saturated fats which are the principal confounding factors of breast cancer. Diets rich in x-6 FA tend to favor development of obesity and cancer [1] [2] [3] and a significant association was established between breast cancer risk and x-6 FA (i.e., linoleic acid and arachidonic acid) concentrations in breast adipose tissue [4] . On the contrary, x-3 FA are polyunsaturated essential FA with anti-inflammatory properties which counteract the pro-inflammatory x-6 FA. Fish oil (FO) diet rich in x-3 FA have beneficial effects in many diseases including various cancers. Decreased consumption of FO during past decade in Japanese women correlates with high incidence of breast cancer [5] . Two main constituents of FO, eicosapentaenoic acid (EPA, C20:5) and docosahexaenoic acid (DHA, C22:6) suppress breast cancer cell growth in vitro and in animal models [6] . A recent study showed that EPA and DHA shifted the pro-survival and proliferative effect of estrogen to a pro-apoptotic effect in human breast cancer cells [7] . Others have shown that EPA and DHA inhibit proliferation of MCF-7 breast cancer cells [8] . A clinical study showed that EPA and DHA intake were inversely associated with breast cancer risk in post-menopausal women [9] . Clinical and experimental works suggest that x-3 FA are potentially protective against promotion and progression stages of breast cancers by enhancing apoptosis, and are also found to be very effective during chemotherapy [10] . Though other organs such as lungs, liver, and brain are involved, bone remains the prevalent site for breast cancer metastasis [11, 12] . Bone metastasis of breast cancer cells is often facilitated due to the permissive nature of the fenestrated bone marrow endothelial lining called sinusoids [13] . Colonized breast cancer cells in the bone microenvironment cause maturation and activation of osteoclasts to form osteolytic lesions leading to severe pain and bone fracture.
Evidence over the past 20 years has shown that EPA and DHA are beneficial for bone health [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Further, recent evidence suggests the DHA may have more potent bioactivity in bone than EPA [15, 18, 30, 31] . DHA had more potent anti-inflammatory effects relative to EPA, with marked attenuation of NF-jB activation and TNF-a secretion in macrophages [32] [33] [34] . DHA specifically enhanced anti-inflammatory IL-10 secretion and reduced the expression of pro-inflammatory M1 (F4/80
? /CD11 ? ) macrophages [32] . In addition, DHA is more potent inhibitor of bone resorbing osteoclast formation than EPA [18, 35] . DHA supplementation in rat showed that DHA accumulated in the osteoblast-rich and nerve-abundant periosteum of femur and appears to be a vital constituent of marrow and periosteum of healthy modeling bone [36, 37] . A few studies have also suggested preventive effect of DHA against ovariectomy-induced bone loss in rat [15, 23, 38] . Use of x-3 FA specifically DHA against cancer is gaining attention. DHA has been shown to reduce tumor incidence by 30 % and led to increased BRCA-1 protein expression in rats [39] . DHA also up-regulated syndecan-1 (SDC-1) in human breast cancer cells and induces apoptosis by activating PPARc [40] . Breast cancer cell proliferation was inhibited by DHA through proteasomedependent degradation of estrogen receptor-alpha, reduced cyclin-D1 expression, as well as inhibited MAPK signaling [41] . DHA has potent anti-angiogenic effects inhibiting production of many important angiogenic mediators such as VEGF, PDGF, PDECGF, COX-2, PGE2, nitric oxide, NF-jB, matrix metalloproteinases, and b-catenin [42] . DHA is also known to act as a chemo-preventive agent by inducing apoptosis through different mechanisms, such as the up-regulation of MAP-kinase-phosphatase-1 (MKP-1) and down-regulation of ERK1/2 and p38 MAPKs [43] and externalization of phosphatidylserine and membrane disruption [44] . DHA has been found to act synergistically with chemotherapeutic drugs by modulating the tumor cell response to them. FO diet, rich in EPA and DHA, has been shown to affect primary breast tumor growth and metastasis to bone [45] . However, the role of individual x-3 FA such as EPA and DHA on breast cancer bone metastasis and associated osteolysis has not been investigated yet. In the present study, we examined the effect of EPA-rich-FO and DHA-rich-FO diets on breast cancer metastasis to bone and associated osteolysis. Finally, we also determined if DHA can improve the sensitivity to drug to doxorubicinresistant MCF-7 breast cancer cells.
Materials and methods

Materials
The MDA-MB-231 and doxorubicin registrant MCF-7 cell lines were purchased from American Type Culture Collection (Rockville, MD) and maintained at 37°C in Dulbecco's modified essential medium (DMEM) supplemented with 10 % fetal calf serum (FCS) and penicillin and streptomycin. The x-3 FA, DHA and EPA ,and corn oil (CO) were purchased from Cayman Chemical Company (Ann Arbor, MI). EPA-rich FO (EPA-FO) and DHA-rich FO (DHA-FO) were obtained from Ocean Canada Ltd (Dartmouth, NS). pGL3-control vector (Luciferase reporter plasmid containing firefly luciferase gene) was purchased from Promega (Madison, WI). Antibodies against CD44, P-glycoprotein (P-gp), and b-actin were purchased from Santa Cruz (Dallas, TX). TRAP staining reagent was purchased from Sigma (St. Louis, MO).
Generation of MDA-MB-231-Luc cell line MDA-MB-231-Luc was established by the stable transfection of firefly luciferase gene (PGL3-control vector) using Lipofectamine Plus Reagent (Life Technologies Inc., Grand Island, NY). pcDNA3 vector (Invitrogen Co, Carlsbad, CA) was co-transfected for the selection by G418 (Sigma, St. Louis, MO). Luciferase quantification was performed using the Luciferase Assay System (Promega, Madison, WI).
Cell proliferation assay MDA-MB-231 and MDA-231 Luc cells were plated at a density of 2 9 10 4 cells/100 ll per well in a 96-well plate. Cells were allowed to adhere overnight and replaced with fresh media and FA. After 48 h of incubation, 20 ll MTS reagent was added to each well, and incubated for 4 h at 37°C. Absorbance was read at 490 nm wavelength.
Invasion assay 2 9 10 4 cells in 200 ll serum free DMEM were added to upper chamber and 700 ll of DMEM supplemented with 10 % FCS and FA were added to the lower chamber of a 24-well BioCoat Matrigel invasion assay plate (BD Biosciences, Bedford, MA). After 48 h of incubation, cells which had migrated through the pores to the lower side of the membrane were fixed with 10 % formalin and stained with 0.1 % crystal violet blue and counted.
Animals, experimental diets, and feeding
The 3-week-old athymic NCr-nu/nu female mice were obtained from NIH animal facilities and used according to the approved protocol by the Animal Care and Use Committee (IACUC). CO, EPA-FO, and DHA-FO diets were prepared in our laboratory as previously described [17] . The composition of food is provided in Table 1 . The mice were fed a diet containing experimental diets for 4 weeks prior to the intra-cardiac/intra-tibial injection of breast cancer cells.
Quantitative assessment of tumor burden in visceral organs
After 4 weeks post-injection of MDA-MB-231 Luciferase tumor cells, animals were sacrificed and luciferase activity was quantified in different organs as described previously [46] .
Generation of osteolytic and visceral metastasis in nude mice animal model: intra-cardiac method After 4 weeks of dietary treatment, mice were injected with 1 9 10 5 cells in 100 ll of PBS intra-cardially as described previously [46, 47] . The mice were maintained in their respective diets for 4 weeks post-injection and performed X-ray as described previously [46, 47] . The radiolucent osteolytic areas of bone metastasis were quantified using a computer-assisted MetaMorph analysis program.
Histological analysis of bone lesions
In parallel to radiographic analysis, radiographically affected and unaffected forelimb and hindlimb long bones were excised, fixed in 10 % formalin in PBS (pH 7.2) for 2 days, then decalcified. Subsequently, they were embedded in paraffin and stained with hematoxylin and eosin (H&E) as previously described [47] .
Tartrate-resistant acid phosphatase (TRAP) and CD44 staining of bones Tartrate-resistant acid phosphatase (TRAP) staining of bone sections was performed as described previously [48] . Osteoclasts were visualized by using a TRAP kit (Sigma #387A-1KT). CD44 positive cells were visualized using monoclonal antibody against CD44 (Santa Cruz) following the manufacturer's instructions.
Generation of osteolytic tumors in nude mice animal model: intra-tibial method After 4 weeks of dietary treatment, an IP injection of Buprenorphine HCL (essentially equivalent to that of morphine on a milligram basis) at 2 mg/kg body weight was given for operative pain. Then, under general anesthesia, the patella skin was washed with a betadine solution and dried. A superficial skin incision was made in the skin overlying the patella using scissors. A 30-gauge needle was inserted at the level of the intercondylar notch and into the medullary canal to create an initial core pathway, followed by insertion of a 29-gauge needle to make the final pathway into the bone. Then, 10 ll PBS containing 1 9 10 6 cells was very slowly injected using a 25 ll Hamilton syringe with a 29-gauge needle to prevent leakage of cells outside the bone. Skin wound was closed using silk threads (4-0, Ethicon). After surgery, neomycin/polymyxin B/bacitracin zinc ophthalmic ointment (Bausch & Lomb Pharmaceuticals) was applied to the wound. The mice were maintained in their respective diets for 4 weeks post-injection. X-ray and tissue histology were performed as described above.
Proliferation, invasion, and P-gp expression in MCF7dox cells Proliferation and invasion assays are done as described above and P-gp expression was analyzed by western blot as described previously [14] .
Statistical analysis
Data are presented as mean values ± SEM. Differences among the groups were tested by one-way analysis of variance and Student's t test. Newman-Keuls post hoc test was used followed by ANOVA if multiple correlations were made. A p value \ 0.05 was considered statistically significant. The analyses were performed with Graphpad prism (La Jolla, CA).
Results
Effect of EPA and DHA on proliferation and invasion of breast cancer cell
To examine the effect of EPA and DHA on the breast cancer cell load, we performed MTS cell proliferation added to the lower chamber in a 24-well BioCoat Matrigel invasion coated chamber inserts with 8-lm pore size membranes. After 48 h of incubation, the remaining upper chamber cells were removed and cells which had migrated through the pores to the lower side of the membrane were fixed with 10 % formalin and stained with 0.1 % crystal violet blue and counted manually. Each value represents the mean ± SEM of two independent triplicate cultures. Number denotes lM concentration of fatty acids. p value \ 0.05 was considered significant by Student's t test. *p \ 0.05 vs. EPA 100; # p \ 0.05 vs. LA 100; **p \ 0.05 vs. EPA 50 assay of MDA-MB-231 and MDA-MB-231-Luc cell lines. Our data demonstrated that DHA more potently inhibited the breast cancer cell proliferation than EPA (Fig. 1a, b) . The metastasis of the tumor cells requires the local intravasation, which involves passing through the extracellular matrix. Therefore, to examine the effect of EPA and DHA, we performed an invasion assay using a collagencoated membrane in the culture wells. DHA inhibited the migration of the breast cancer cells through the collagen membrane more potently than EPA (Fig. 1c, d) . These results indicate that DHA inhibits both proliferation and invasion of breast cancer cells more potently than EPA.
Effect of EPA and DHA on breast cancer metastasis to bone after intra-cardiac injection of breast cancer cells
To determine the effect of EPA and DHA on the levels of breast cancer cell metastasis to bone, we performed H&E staining of bone section collected form mice injected with breast cancer cells intra-cardially. Bone samples from DHA-FO treated mice showed the lowest load of breast cancer cell as compared to CO and EPA-FO treated mice (Fig. 2) .
Effect of EPA and DHA on osteolysis due to breast cancer metastasis to bone after intra-cardiac injection of breast cancer cells
To determine the effect of EPA and DHA on breast cancer bone metastasis associated osteolysis, we measured the osteolytic lesions by X-ray. DHA-FO treated mice showed the lowest number of osteolytic lesions as compared to CO and EPA-FO treated mice (Fig. 3) .
Effect of EPA and DHA on breast cancer cell load in different organs after intra-cardiac injection of breast cancer cells
To determine the effect of EPA and DHA on the metastasis of breast cancer cell to the different organs, we determined the luciferase activity of different organs from the mice injected with MDA-MB-231-Luc intra-cardially. Bone samples from DHA-treated mice showed the lowest level of luciferase expression as compared to CO and EPA-FO treated mice (Fig. 4) . However, breast cancer metastasis to the other organs was not significantly different among the groups. These results indicate that DHA inhibits breast cancer metastasis specifically to bone more potently than EPA.
Effect of EPA and DHA on the expression of CD44 and TRAP in bone after intra-cardiac injection of breast cancer cells
We examined the effect of EPA and DHA on the expression of CD44 on the bone sections by immunostaining. Both EPA-FO and DHA-FO significantly reduced the CD44 protein expression in bone as compared to CO groups (Fig. 5A) . However, DHA-FO reduced the CD44 expression in bone more potently than EPA-FO (Fig. 5A,  B) . To determine the effect of EPA and DHA on the osteoclasts levels on the breast cancer metastasized bone, we performed TRAP staining of bone sections. Interestingly, a reduction of number of TRAP positive osteoclasts is observed in DHA-FO treated mice as compared to CO and EPA-FO treated mice (Fig. 5C ). However, there was not much difference between CO and EPA-FO treated groups (Fig. 5C ).
Effect of EPA and DHA on breast cancer cell load and associated osteolysis after intra-tibial injection of breast cancer cell
To determine if direct injection of breast cancer cells into the bone can induce osteolysis and whether EPA and DHA have any effect on the proliferation and breast cancer- Fig. 3 Effect of EPA and DHA on osteolysis due to breast cancer metastasis to bone after intra-cardiac injection of breast cancer cells. The athymic NCr-nu/nu female mice were fed a diet containing CO or EPA-FO or DHA-FO for 4 weeks prior to the intra-cardiac injection of the MDA-MB-231 (A) or MDA-MB-231-Luc (C) cells. The mice were then injected with 1 9 10 5 cells in 100 ll of PBS intracardially. The mice were maintained in their respective diets for 4 weeks post-injection. Deeply anesthetized animals were exposed to X-ray using a Faxitron radiographic inspection unit. Osteolytic lesions are shown in X-ray (A, C). The radiolucent osteolytic areas of bone metastasis were marked and quantified for MDA-MB-231 (B) or MDA-MB-231-Luc (D) injected mice using a computer-assisted MetaMorph analysis program. n = 5 mice per group. Each value represents the mean ± SEM. Values with different superscripts are significantly different at p \ 0.05 by Newman-Keuls one-way ANOVA with multiple comparison test associated osteolysis, we injected breast cancer cells intratibially. DHA-FO group significantly inhibited the proliferation of breast cancer cells in bone as compared to EPA-FO and CO treatment groups (Fig. 6A, B) . However, there was no difference between CO and EPA-treated mice. Similarly, DHA-FO group significantly inhibited osteolysis of breast cancer injected bone as compared to CO and EPA-FO treated groups (Fig. 6C, D) . EPA-treated mice showed slightly less osteolysis as compared to CO group, however, not significant.
Effect of DHA on proliferation, invasion, and P-gp expression on doxorubicin-resistant MCF-7 breast cancer cell To determine if DHA can improve sensitization of doxorubicin-resistant breast cancer cell to doxorubicin, we performed in vitro culture of MCF-7dox in the presence of doxorubicin and DHA alone and in combination. Interestingly, DHA treatment alone appeared to be significant in decreasing proliferation of MCF-7-dox cells as compared to control and doxorubicin alone (Fig. 7A) . As expected, doxorubicin alone did not inhibit proliferation of MCF7dox cell sufficiently. However, doxorubicin could dramatically inhibit the proliferation of MCF-7dox cell in the presence of DHA (Fig. 7A) . We also performed the invasion study to see if DHA can suppress the invasion of MCF-7dox cell. Doxorubicin alone did not inhibit the invasion of MCF-7dox cell. Similar to the anti-proliferative effect, treatment with DHA alone appeared to be significant in inhibiting the invasion of MCF-7-dox cells as compared to control and doxorubicin alone (Fig. 7B) . Interestingly, doxorubicin in the presence of DHA further enhanced the inhibitory effect of DHA on invasion. One of the major causes for cancer cells to resist current chemotherapy is attributed to the over-expression of P-gp, resulting in insufficient drug delivery to the tumor sites [49] . Therefore, we determined the levels of P-gp in MCF-7dox cells treated with DHA and doxorubicin alone or in combination. Interestingly, DHA alone or in combination with doxorubicin decreased the level of P-gp in MCF-7dox cell (Fig. 7C) .
Discussion
Breast cancer cell metastasis to bone and related osteolysis is one of the major causes of morbidity and mortality in breast cancer patients [11] . In breast cancer patients, osteolytic lesions frequently occur in the load-bearing bones with increased susceptibility to pathological fracture. It has been demonstrated that EPA and DHA x-3 FA rich FO prevents breast cancer cell metastasis to bone [45] . However, it was not known whether EPA or DHA or both are the bioactive component that is exerting this inhibition of breast cancer cell metastasis to bone. In this study, we demonstrated for the first time that the DHA not the EPA attenuates the breast cancer metastasis to bone by inhibiting proliferation and invasion of breast cancer cells, as well as osteolysis by inhibiting breast cancer stimulated bone resorbing osteoclast formation. Osteolysis does not occur due to direct effect of breast cancer cells metastasized to the bone. Rather stimulation of osteoclast maturation and their activation cause formation of bone lesions [11, 12] . The colonized breast cancer cells produce TNF-a and IL-6, which along with PTHrP and IL-11 stimulate the bone marrow stromal cells and residing osteoblasts to synthesize more RANKL to activate osteoclasts [12, 50] which ultimately results in the formation of osteolytic lesions. Enhanced proliferation of breast cancer cells in the bone was found to be associated with enhanced osteoclast formation in our study. We previously showed that DHA not EPA potently inhibited osteoclastogenesis by suppressing TNF-a and NF-jB signaling [18] . In this study, we found that DHA-FO treated mice exhibited significantly less burden of breast cancer cells as well as osteoclasts as compared to EPA-FO and x-6 FA rich CO groups. These data together with in vitro cell culture data indicate that DHA attenuates breast cancer bone metastasis and related osteolysis by inhibiting proliferation and migration of breast cancer cells to the bone as well as by reducing osteoclast activity in the bone.
Recent reports demonstrate a positive role of CD44 in the progression of metastasis [51, 52] . Many cancer cells including breast cancer cells hyper express the cell surface adhesion protein CD44 [53, 54] . Nakamura et al. [55] have demonstrated that metastasized breast cancer cells expressing CD44 are present on the bone surface that faces the bone resorbing osteoclasts. CD44 acts as the main glycoprotein receptor for the disaccharide hyaluronan, a major component of the luminal surface of the bone marrow capillary endothelium. Thus, metastatic breast cancer cells expressing high levels of CD44 may be efficiently recruited to bone marrow. Similarly, collagen I, a constituent of bone matrix, serves as a ligand for CD44, indicating efficient recruitment of breast cancer cells to the bone. In a recent study, Mandal et al. showed that both EPA and DHA inhibit CD44 mRNA and protein levels in MDA-MB-231 cells when cultured in the presence of EPA and DHA [45] . Further, they demonstrated that breast cancer tumor xenografts from FO-treated mice had reduced levels of CD44 mRNA and protein when mice were injected with MDA-MB-231 cells in their mammary fat pad [45] . Our results show that bones from DHA-FO treated mice had a reduced expression of CD44 protein compared to the EPA-FO treated mice when injected with MDA-MB-231 breast cancer cells intra-cardially, thus, providing a mechanism for the attenuation of breast cancer cell migration/invasion by DHA. Furthermore, for the first time, we demonstrate that DHA prevents the formation of osteolytic lesions in the bone more potently than EPA when breast cancer cells are injected either intra-cardially or intra-tibially. Moreover, CD44 has been shown to bind and retain the protein MMP-9, which is present on the surface of breast cancer cells [56] . MMP-9 cleaves collagen I in the bone matrix and may contribute to induce osteolysis found in bone, resulting from breast cancer metastasis. MDA-MB-231 cells also induced an increase in the expression of MMP-9 by migrating osteoclasts [57] . We previously showed that DHA inhibited osteoclastogenesis more potently than EPA by suppressing the expression of MMP-9 [18] . Others have shown that DHA inhibits MMP-9 expression in breast cancer cells via heme oxygenase-1 [58] . Therefore, DHAmediated prevention of osteolysis in breast cancer metastasized bone is likely to be associated with the modulation of MMP-9 expression in bone microenvironment, thereby attenuating bone resorbing osteoclast formation in bone. In our study, reduced expression of CD44 and TRAP in the DHA-FO treated bone revealed that DHA may prevent breast cancer bone metastasis associated osteolysis by attenuating invasion and bone resorbing osteoclast formation. Recently, a number of studies show that x-3 FA, especially DHA, can act as an excellent adjuvant to enhance the effect of various drugs [59] [60] [61] . It has been reported that tumor cells can be made more sensitive to chemotherapy than non-tumor cells when membrane lipids are enriched with DHA [62] . In a recent phase II clinical trial, Bouqnoux et al. [62] demonstrated that DHA during chemotherapy was devoid of adverse side effects and can improve the outcome of chemotherapy when highly incorporated. DHA has the potential to specifically chemosensitize tumors. Doxorubicin chemosensitization of breast cancer cell lines by DHA was reported to be cell-line selective, affecting MDA-MB-231 and MCF-7dox (a doxorubicinresistant cell line) but not the parental MCF-7 cell line [63] . Chemosensitization through FA appears as a new promising adjuvant therapeutic paradigm, since x-3 FA are physiological molecules found in food and are non-toxic in vivo. We performed further studies to determine if DHA can improve the drug sensitivity of drug-resistant breast cancer cells, doxorubicin-resistant MCF-7 (MCF-7dox). One of the major causes for cancer cells to resist current chemotherapy is attributed to the over-expression of P-gp, resulting in insufficient drug delivery to the tumor sites [49] . Our study showed that DHA efficiently improved the sensitivity to doxorubicin to MCF-7dox breast cancer cells by suppressing the expression of P-gp in breast cancer cells. However, further in vivo preclinical studies are needed to establish this effect.
Conclusion
Breast cancer cells metastasis to bone is one of the most catastrophic complications for the morbidity and mortality of breast cancer patients. Our results provide preliminary evidence suggesting that the use of DHA supplements alone or in combination with anti-cancer drugs could be an important therapy for this devastating disease. However, further studies are required to determine details behind the mechanisms of how DHA exerts its effect against breast cancer cell progression and metastasis to bone. Our results identify a novel function of a bioactive FO component, DHA as a promising dietary drug to prevent/treat breast cancer progression and bone metastasis and related osteolysis. Fig. 7 Effect of DHA on proliferation, invasion, and P-gp expression on doxorubicin-resistant MCF-7 breast cancer cell. For cell proliferation assay, MCF-7dox cells were plated in a 96-well plate. After 24 h of incubation, cells were replenished with fresh media with different concentrations of DHA and doxorubicin (2 lM) alone or in combination. Cells were then incubated for an additional 48 h. At the end of incubation, 20 ll MTS reagent was added to each well, and incubated for 4 h at 37°C. Absorbance was read at 490 nm. For invasion assay, MCF-7dox cells in 200 ll serum free DMEM were added to upper chamber and 700 ll of DMEM supplemented with 10 % fetal calf serum (FCS) and DHA (50 lM) and doxorubicin (2 lM) alone or in combination added to the lower chamber in a 24-well BioCoat Matrigel invasion coated chamber inserts with 8-lm pore size membranes. After 48 h of incubation, the remaining upper chamber cells were removed and cells which had migrated through the pores to the lower side of the membrane were fixed with 10 % formalin and stained with 0.1 % crystal violet blue and counted manually. P-gp protein levels were analyzed in MCF-7dox cells treated with 50 lM of DHA and 2 lM of doxorubicin alone or in combination for 48 h by western blot. Each value represents the mean ± SEM of two independent triplicate cultures. 
